Oticon Foundation in large cancer therapy venture
The Oticon Foundation's investment arm, William Demant Invest, is buying 85 percent of shares in a large international medtech company that produces equipment for cancer diagnostics. "In our context, it is a significant acquisition," says CEO Niels Jacobsen.
The Danish investment company William Demant Invest, 100 percent owned by the Oticon Foundation, which sits on the share majority in the hearing aid group William Demant has just announced that it is acquiring the UK and international company Vision RT that produces products for radiation treatment of cancer tumors.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Denmark’s hearing device king abdicates
For abonnenter
